Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-EHA 2025 Multiple Myeloma Highlights
02 July 2025 | Virtual Meeting
Post-EHA 2025 Multiple Myeloma Highlights
Featuring presentations & discussions on selected myeloma abstracts from the 30th Congress of the European Hematology Association (EHA).
Chair: Faith Davies | Moderators: Charlotte Pawlyn & Ciara Freeman
The Post-EHA 2025 Multiple Myeloma webinar has been supported by a silver sponsorship from Johnson & Johnson and Legend Biotech. Supporters have had no influence over the production of this activity.
Session 1: Optimizing frontline therapy in newly diagnosed multiple myeloma
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (ISA-KRD) for high-risk (HR) newly diagnosed multiple myeloma (NDMM): first-time report of the full cohort of transplant-eligible (TE) patients in the GMMG-CONCEPT trial
Lisa Leypoldt University Medical Center Hamburg, Eppendorf, Germany
Daratumumab + bortezomib/lenalidomide/dexamethasone in transplant-eligible newly diagnosed multiple myeloma: analysis of sustained minimal residual disease negativity in the Phase lll PERSEUS trial
Meral Beksac Istinye University Ankara Liv Hospital, Turkey
Daratumumab, bortezomib, lenalidomide and dexamethasone (DVRD) vs VRD in transplant-ineligible/transplant-deferred newly diagnosed multiple myeloma: Phase lll CEPHEUS trial cytogenetic subgroup analysis
Saad Usmani Memorial Sloan Kettering Cancer Center, New York, NY, United States
Panel discussion
Session 2: Novel combinations for high-risk and heavily pretreated myeloma patients
DREAMM-8 study of belantamab mafodotin + pomalidomide + dexamethasone vs pomalidomide + bortezomib + + dexamethasone in relapsed/refractory multiple myeloma: a high-risk cytogenetic subgroup analysis
Meletios Dimopoulos University of Athens School of Medicine, Athens, Greece
Isatuximab subcutaneous via an on-body delivery system versus isatuximab intravenous, plus pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma: the randomized Phase lll IRAKLIA study
Xavier Leleu Poitiers University Hospital, Poitiers, France
Panel discussion
Session 3: Expanding clinical evidence for CAR T-cell therapy in myeloma
Phase ll registrational study of anitocabtagene autoleucel for relapsed and/or refractory multiple myeloma (RRMM): Updated results from IMMAGINE-1
Gurbakhash Kaur Mount Sinai School of Medicine, New York, NY, United States
Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma
Sundar Jagannath Mount Sinai School of Medicine, New York, NY, United States
Panel discussion
Session 4: Novel T-cell engagers in newly diagnosed and relapsed myeloma
Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MAGNETISMM-6 part 1
Meletios Dimopoulos University of Athens School of Medicine, Athens, Greece
MAGNETISMM-30: A Phase lb, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)
Alexander Lesokhin Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Phase ll study of talquetamab + teclistamab in patients with relapsed/refractory multiple myeloma and extramedullary disease: REDIRECTT-1
Shaji Kumar Mayo Clinic, Rochester, MN, United States
Linvoseltamab + carfilzomib in patients with relapsed/refractory multiple myeloma: Initial results from the linker-MM2 trial
Enrique Ocio Marqués de Valdecilla University Hospital, Santander, Spain
First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody, in patients with relapsed/refractory multiple myeloma: Initial Phase l results
Rakesh Popat University College London Hospitals NHS Foundation Trust, London, United Kingdom
Panel discussion
